

Applicant: Rudi D. NEIRINCKX
Application No. 09/584,978
Attorney Docket No. 2502491-991110
(formerly 44334)

IN THE SPECIFICATION:

Page 1, after the second paragraph, insert the following:

The invention relates to means for delivering, for example, EGF to a psoriatic site. Topical formulations or systemic administration can be used. The amount of EGF can range from 0.01 to 50 ug/g. The composition can contain 0.5-20 ug/g of EGF. The formulation also can contain other ingredients, such as anti-inflammatory products.

EGF precursors, such as FGF, or molecules with similar function, such as urogastrone or EGF truncations can be used.